MHC I expression is typically epigenetically downregulated in most SCLC cases; however, a small yet unique subset with a non-neuroendocrine phenotype (ASCL1- and NEUROD1-negative) may de-repress MHC I expression, leading to significant clinical benefits from immunotherapy [20]. The gene discussed is ASCL1; the disease is small cell lung carcinoma.